{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:41:57Z","timestamp":1788273717201,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Trade, Industry &amp; Energy (MOTIE, Korea).","award":["RS-2024-00400101"],"award-info":[{"award-number":["RS-2024-00400101"]}]},{"name":"Soonchunhyang University Research Fund","award":["2025-0043"],"award-info":[{"award-number":["2025-0043"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>This study aimed to elucidate the oncogenic role of FOXA1(forkhead box A1) in ovarian cancer and to evaluate its potential as both a therapeutic target and a diagnostic biomarker. We further investigated whether FOXA1 inhibition could enhance responsiveness to immune checkpoint blockade and overcome chemoresistance. A total of seventy-six ovarian tissue samples were analyzed, including nine normal, thirty-four benign, and thirty-three malignant specimens. IHC (immunohistochemistry) staining was performed to assess FOXA1 expression and its correlation with tumor stage. Functional studies were conducted using FOXA1 siRNA in SK-OV3 and HEYA8 cell lines. Changes in cell proliferation, migration, invasion, and wound-healing ability were evaluated following FOXA1 silencing. Quantitative RT-PCR was used to measure the expression of FOXA1 and EMT (epithelial\u2013mesenchymal transition)-related genes. The effects of FOXA1 inhibition on sensitivity to carboplatin and the immune checkpoint inhibitor atezolizumab were also examined. IHC analysis revealed significant differences in FOXA1 expression among normal, benign, and malignant tissues, with levels correlating with tumor stage. FOXA1 silencing significantly reduced proliferation and decreased migration and invasion by 60\u201380%, accompanied by marked downregulation of EMT-related genes. Moreover, FOXA1 inhibition enhanced atezolizumab responsiveness and reduced carboplatin resistance in ovarian cancer cells. In summary, FOXA1 acts as an oncogenic driver in ovarian cancer, promoting proliferation, invasion, and EMT activation. Its overexpression correlates with disease progression, supporting its potential as a biomarker and therapeutic target. Targeting FOXA1 could enhance immunotherapy efficacy and help overcome chemoresistance in ovarian cancer.<\/jats:p>","DOI":"10.3390\/ijms27031194","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:14:23Z","timestamp":1769415263000},"page":"1194","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1455-2343","authenticated-orcid":false,"given":"Taewan","family":"Kim","sequence":"first","affiliation":[{"name":"Future Innovation Medical Research Center, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8650-3092","authenticated-orcid":false,"given":"Jaesung","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Medical Life Science, Soonchunhyang University, Asan 31538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-8472","authenticated-orcid":false,"given":"Hyejeong","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Medical Life Science, Soonchunhyang University, Asan 31538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6561-4361","authenticated-orcid":false,"given":"Beamjun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medical Life Science, Soonchunhyang University, Asan 31538, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-1225","authenticated-orcid":false,"given":"Kwangseock","family":"Kim","sequence":"additional","affiliation":[{"name":"Future Innovation Medical Research Center, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-3519","authenticated-orcid":false,"given":"Eunjung","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-0365","authenticated-orcid":false,"given":"Taesung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5230-1997","authenticated-orcid":false,"given":"Seob","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Gynecology, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.21037\/gs-20-325","article-title":"Secondary and tertiary ovarian cancer recurrence: What is the best management?","volume":"9","author":"Garzon","year":"2020","journal-title":"Gland. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102074","DOI":"10.1016\/j.canep.2021.102074","article-title":"Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study","volume":"76","author":"Gaitskell","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alexandrova, E., Pecoraro, G., Sellitto, A., Melone, V., Ferravante, C., Rocco, T., Guacci, A., Giurato, G., Nassa, G., and Rizzo, F. (2020). An overview of candidate therapeutic target genes in ovarian cancer. Cancers, 12.","DOI":"10.3390\/cancers12061470"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Network","year":"2011","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/cimb44010021","article-title":"Circulating exosomal miR-1290 for diagnosis of epithelial ovarian cancer","volume":"44","author":"Jeon","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Yu, C., Li, X., Zhao, Y., and Hu, Y. (2023). The role of FOXA family transcription factors in glucolipid metabolism and NAFLD. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1081500"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1210\/en.2013-1843","article-title":"Foxa1 and Foxa2 regulate \u03b1-cell differentiation, glucagon biosynthesis, and secretion","volume":"155","author":"Poisson","year":"2014","journal-title":"Endocrinology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"116324","DOI":"10.1016\/j.celrep.2025.116324","article-title":"Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer","volume":"44","author":"Formaggio","year":"2025","journal-title":"Cell Rep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Seachrist, D.D., Anstine, L.J., and Keri, R.A. (2021). FOXA1: A pioneer of nuclear receptor action in breast cancer. Cancers, 13.","DOI":"10.3390\/cancers13205205"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.canlet.2015.03.008","article-title":"FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer","volume":"361","author":"Zhang","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41420-024-01936-1","article-title":"FOXA1 and FOXA2: The regulatory mechanisms and therapeutic implications in cancer","volume":"10","author":"Liu","year":"2024","journal-title":"Cell Death Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.32074\/1591-951X-217","article-title":"High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer","volume":"113","author":"Sheta","year":"2021","journal-title":"Pathologica"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Urz\u00faa, U., Chac\u00f3n, C., Norambuena, M., Lizama, L., Sarmiento, S., Asaki, E., Powell, J.I., and Ampuero, S. (2020). The ovarian transcriptome of reproductively aged multiparous mice: Candidate genes for ovarian cancer protection. Biomolecules, 10.","DOI":"10.3390\/biom10010113"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107712","DOI":"10.1016\/j.isci.2023.107712","article-title":"A single-cell landscape of pre-and post-menopausal high-grade serous ovarian cancer ascites","volume":"26","author":"Chen","year":"2023","journal-title":"IScience"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.3892\/mmr.2016.5583","article-title":"The clinical significance of forkhead box protein A1 and its role in colorectal cancer","volume":"14","author":"Ma","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000519129","article-title":"Expression of FOXA1 is associated with the tumor-infiltrating M2 macrophage, cytotoxic T lymphocyte, and effect of chemotherapy in bladder cancer","volume":"107","author":"Wang","year":"2023","journal-title":"Urol. Int."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Paw\u0142owska, A., Rekowska, A., Kury\u0142o, W., Pa\u0144czyszyn, A., Kotarski, J., and Wertel, I. (2023). Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310859"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2023.06.018","article-title":"Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050\/GOG 3015\/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III\/IV ovarian cancer","volume":"177","author":"Pignata","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41698-024-00640-8","article-title":"Spatial tumor immune microenvironment phenotypes in ovarian cancer","volume":"8","author":"Mateiou","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2019.05.021","article-title":"Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced\/recurrent ovarian and uterine cancers","volume":"154","author":"Liu","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE\/ENGOT-ov29 Trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kong, H.-J., Kang, D.-H., Ahn, T.-S., Kim, K.-S., Kim, T.-W., Lee, S.-H., Lee, D.-W., Ryu, J.-S., and Beak, M.-J. (2023). The role of CPNE7 (Copine-7) in colorectal cancer prognosis and metastasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316704"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1194\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T05:21:02Z","timestamp":1769491262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/3\/1194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ijms27031194"],"URL":"https:\/\/doi.org\/10.3390\/ijms27031194","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]}}}